REBECCA ASHBURN: Open Payments
NPI 1598338824 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,164 in 53 payments from 26 companies in 2025. Trend: 2023 $1,137 · 2024 $1,016 · 2025 $1,164
Food & beverage: $1,064Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $189 |
| ABBVIE INC. | 8 | $135 |
| Syndax Pharmaceuticals, Inc. | 3 | $70 |
| SOBI, INC | 3 | $67 |
| Incyte Corporation | 3 | $64 |
| GENZYME CORPORATION | 3 | $64 |
| Janssen Biotech, Inc. | 3 | $57 |
| Celgene Corporation | 2 | $54 |
| SANOFI-AVENTIS U.S. LLC | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
Products named: Xospata, REVUFORJ, VENCLEXTA, Vonjo, REBLOZYL, EPKINLY, MONJUVI, REZUROCK.
Industry payments across CO — which companies pay providers there.
